Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Imagion Biosystems Ltd. ( (AU:IBX) ) has issued an announcement.
Imagion Biosystems has successfully completed the settlement of Tranche 2 of its $3.5 million Placement, raising $2.85 million in funds. These proceeds will be used to advance the company’s MagSense® imaging technology, specifically targeting the HER2 breast cancer indication, and to initiate studies for prostate and ovarian cancer. The company plans to commence a Phase 2 clinical trial for HER2 breast cancer, with objectives including the submission of an IND application to the FDA, completion of drug manufacturing, filing of new IP applications, and collaborations with MRI experts to enhance their imaging platform.
More about Imagion Biosystems Ltd.
Imagion Biosystems Limited is a healthcare company focused on the early detection of cancer using its proprietary MagSense® imaging technology. The company is primarily engaged in advancing imaging solutions for cancer indications, including HER2 breast cancer, prostate cancer, and ovarian cancer.
Average Trading Volume: 10,350,735
Technical Sentiment Signal: Buy
Current Market Cap: A$10.1M
Find detailed analytics on IBX stock on TipRanks’ Stock Analysis page.